When was $RARE first mentioned on Surfaced?

The earliest tracked mention of $RARE in the Surfaced archive was on Jul 22, 2025.

How many voices track $RARE?

3 FinTwit voices have mentioned $RARE 5 times in the past 12 months.

What kind of voices mention $RARE most?

$RARE is mentioned most by Biotech voices on Surfaced.

Last 12mo stats

mentions

voices

$RARE

Q: Who mentions $RARE most on Surfaced?

@adamfeuerstein (Adam Feuerstein ✡️) mentions $RARE most — 3 mentions in the past 12 months.

Ultragenyx Pharmaceutical

$RARE

Ultragenyx Pharmaceutical

Past 12mo:5mentions3voices

All voices6 mentions past 12mocalls only

Loading price chart…

About this stock

$RARE, the ticker for Ultragenyx Pharmaceutical, has been mentioned 5 times over the past 12 months by 3 distinct FinTwit voices, with the first mention appearing on July 22, 2025. The biotech sector focus dominates discussion, with @adamfeuerstein leading the conversation at 3 mentions, followed by @pelositracker with 2 mentions and @jonerlichman with 1 mention. The most recent mention occurred on July 9, 2026.

AI-generated from tracked posts · updated Jul 18, 2026

Frequently asked

Who mentions $RARE most on Surfaced?

Related stocks

$AGIOAgios Pharmaceuticals

$CYTKCytokinetics

$BBIOBridgeBio Pharma

$APLSApellis Pharmaceuticals

Recent mentions

6 mentions

@pelositrackerJul 9, 2026 · 2:51 PM

This is why we do it Back in April, we flagged Cisneros buying $BBIO ahead of an FDA decision Today, a rival company's heart drug failed a major clinical trial. That leaves BridgeBio as one of the only approved treatments for the same patients Since that tweet, it's up ~20% and just hit all time highs He still hasn't sold his pharma picks: • $AGIO is up +27% • $RARE is up +50% since the tweet

Open on X

@pelositrackerApr 8, 2026 · 3:15 PM

New: Gil Cisneros (D) just filed up to $1,300,000 of new stock trades The ones that stood out are 3 pharma picks: $AGIO, $BBIO, and $RARE The crazy part is that all 3 had major FDA decisions go their way within weeks. every stock is up 10-26% Cisneros doesn't sit on a single health committee but 3/3 on FDA decisions is pretty good

Open on X

@jonerlichmanSep 25, 2025 · 8:46 PM

$APLS $LEGN $RARE $TGTX $ACOG $CYTK $CRNX $CLPT $SDGR $SLP https://t.co/AAhdn49DMo

Open on X

@adamfeuersteinJul 31, 2025 · 12:39 PM

Are we sure Vinay Prasad’s ouster is positive for biotech? Some musings in this week's newsletter. A commonly held view of his three-month tenure running the FDA’s biologics division was that he was more obstructionist and inflexible toward cell and gene therapies than one might have predicted, even accounting for his reputation as a conservative data nitpicker. The FDA rejected $REPL $RARE and $CAPR. Prasad went to war against $SRPT His departure means the FDA will revert to its more permissive, flexible ways, the thinking goes, and that’s good for developers of cell and gene therapies, good for makers of drugs for rare diseases, and a tailwind for biotech overall. I’m not so sure. You know me by now. I have a hard time fully buying into the rosy story. What if Prasad’s replacement as CBER chief is worse? By that, I mean a person who is more politically motivated and more in the MAHA, anti-pharma and anti-vaccine orbit of Health and Human Services Secretary Robert F. Kennedy Jr. Read more at link below, plus some thoughts on the road ahead for $SRPT

Open on X

@adamfeuersteinJul 22, 2025 · 11:03 AM

$REPL rejection follows the rejection of $CAPR and $RARE drugs, and the FDA's actions against $SRPT. CBER Director Vinay Prasad is setting a different tone than his predecessor.

Open on X

@adamfeuersteinJul 17, 2025 · 6:10 PM

The Readout LOUD crew interviewed $RARE CEO Emil Kakkis for this week's podcast. He gave us a fascinating look deep into the FDA's CRL for its San Filippo gene therapy. You'll be amazed at some of the arcane reasons, like not enough temperature probes in a shipping container, that the FDA used to justify delaying the approval. There has been a lot of talk about the ways FDA bureaucracy and red tape slows drug development — and how the agency's new leadership should remove needless obstacles. Emil is frustrated and he offered real-life examples. Listen tonight or over the weekend.

Open on X